Diabetes Treatment & Updates
In this video, Kathryn Kreider, DNP, APRN, FAANP, FNP-BC, and Diana Isaacs, PharmD, CDCES, talk about their session at our Practical Updates in Primary Care 2024 Virtual Series. Drs Kreider and Isaacs talk about how clinicians can individualize care for patients with diabetes, the established benefits of SGLT2 inhibitors and GLP-1 receptor agonists and their benefits on cardiometabolic health, and the importance of screening for mental health comorbidities.
For more meeting coverage, visit the Practical Updates in Primary Care newsroom.
For more information about PUPC 2024 Virtual Series and to register for upcoming sessions, visit https://www.practicalupdates.consultant360.com/.
Kathryn Kreider, DNP, APRN, FAANP, FNP-BC, is a clinical professor of nursing and the director of the Endocrinology Specialty Training Program for nurse practitioners at Duke University School of Nursing (Durham, NC)
Diana Isaacs, PharmD, CDCES, is an endocrine clinical pharmacy specialist and the director of education and training in diabetes technology at the Cleveland Clinic (Cleveland, OH)
TRANSCRIPTION:
Kathryn Kreider, DNP, APRN, FAANP, FNP-BC: Hi everyone, I'm Kathryn Kreider. I'm a professor of nursing at Duke University. I'm also the director of the endocrinology specialty training program at the School of Nursing at Duke. And I practice clinically as a nurse practitioner in adult endocrinology there as well. And I'm joined today by Dr Diana Isaacs.
Diana Isaacs, PharmD, CDCES: Hello everybody, I'm Diana Isaacs. I'm an endocrine clinical pharmacy specialist and also the director of education and training in diabetes technology at the Cleveland Clinic. And I also work in adult endocrinology.
Dr Kreider: So we hope that this session really provided a nice interdisciplinary approach to managing complex patients with diabetes using the most recent standards of medical care from the [American Diabetes Association] ADA as well as other guidelines. We really wanted to provide a comprehensive but succinct approach in managing some of these complex patients.
So we walked through some of the key things. Think about cardiovascular risk reduction and really how we optimize cardiometabolic health for all of our patients, including thinking about things like blood pressure and cholesterol in addition to glycemic reduction. We talked about individualizing treatment for patients. So not everyone needs exactly the same thing. Think about the person in front of you, what their comorbidities are, some of the other factors that should influence their care.
And then Diana went into some of the components of the newest pharmacologic treatments and technology, and I'll let her speak to that.
Dr Isaacs: Yeah, so we see our guidelines are really advocating now SGLT2 inhibitors and GLP-1 receptor agonists because of their benefits on cardiometabolic health, especially for those with established cardiovascular disease, heart failure, and kidney disease.
So big emphasis on that. And then also in terms of technology—continuous glucose monitoring—we are seeing expanded access from Medicare for basically all insulin users or those that are experiencing hypoglycemia. And so we just talk a lot about that as well as how to apply this to actual patient cases.
Dr Kreider: And we wrapped up talking about the importance of screening and assessing for mental health comorbidities and diabetes, as well as avoiding hypoglycemia and a continued emphasis on weight loss and how that can impact cardiometabolic health. So there's a lot of information in our short session and we really hope it was very practical and items that you can take right back to your clinic session and really help improve and optimize the care of your patients with diabetes.